Ascendis Settles YUVIWEL Litigation with BioMarin, Secures Global License
ASND sits 33% above its 52-week low of $186.054.
Summary
Ascendis Pharma and BioMarin have entered a binding term sheet to resolve all litigation over YUVIWEL (navepegritide). BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to continue developing and commercializing navepegritide-related products without restriction, waives certain regulatory rights, and provides a covenant not to sue. Ascendis will pay royalties of 20% on US net sales and 18% in the EU, South Korea, and Brazil through May 20, 2030. This removes a major legal overhang on Ascendis's key growth product, which was approved by the FDA in February 2026 and is already seeing rapid uptake. The settlement clears the path for continued commercialization and supports management's guidance of over €500 million operating cash flow in 2026 and €5 billion revenue by 2030. BioMarin (BMRN) is the counterparty but the news is primarily about Ascendis's product and future royalties.
At the time of this announcement, ASND was trading at $247.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.5B. The 52-week trading range was $186.05 to $282.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.